- Poster presentation
- Open Access
Defining late onset occult asymptomatic cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy: a cardiac magnetic resonance imaging study
© Toro-Salazar et al; licensee BioMed Central Ltd. 2013
- Published: 30 January 2013
- Late Gadolinium Enhancement
- Cardiac Magnetic Resonance Imaging
- Circumferential Strain
- Childhood Cancer Survivor
- Anthracycline Therapy
There are over 270,000 childhood cancer survivors in the US. Of these survivors, more than 50% have been treated with anthracyclines and are at risk of developing progressive cardiotoxicity. Novel cardiac magnetic resonance imaging (CMRI) techniques are now able to reliably detect diffuse myocardial fibrosis and changes in regional myocardial function. We hypothesized that these novel CMRI techniques will identify occult asymptomatic cardiotoxicity in a cohort of childhood cancer survivors with normal global systolic function.
Twenty seven long-term childhood cancer survivors between 11.8-28.8 years with a cumulative dose >240mg/m2 (mean 363±89) and normal systolic function (SF>29%) were studied 2.4-24 years after exposure to anthracycline therapy. Patients underwent CMRI techniques to characterize changes in T1 relaxation time, left ventricular myocardial peak circumferential and longitudinal strain parameters and were analyzed using the 17-segment model. Extracellular volume (ECV) was measured in 13 subjects all of whom were late gadolinium enhancement (LGE) negative. We performed standard CMRI assessment and quantification of myocardial mass, end-systolic and end-diastolic volumes, ejection fraction, and end systolic fiber stress.
In this study we demonstrate that changes in T1 mapping-derived relaxation time and left ventricular myocardial peak circumference strain are present in asymptomatic post-chemotherapy childhood patients who have normal standard CMRI parameters. Circumferential strain analysis and measurement of the T1 myocardial relaxation time by CMRI may accurately identify occult cardiovascular dysfunction in patients exposed to high dose anthracyclines. Thus, this may aid in the evaluation of therapies aimed at reducing adverse cardiac remodeling and preventing heart failure in childhood cancer survivors exposed to anthracyclines.
St. Baldrick's Foundation Supportive Care Research Grant
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.